AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03138174 — intervention group
Intervention type: DEVICE
Intervention: OneTouch Verio Flex Blood Glucose Monitoring System
Description: Blood Glucose Monitoring System
Study NCT02967614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [A]
Description: One eye drop(about 40ul) / Day1 \~ Day8 / BID
Study NCT02967614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [B]
Description: One eye drop(about 40ul) / Day1 \~ Day92 / BID
Study NCT02967614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [A]+[B](1)
Description: One eye drop(about 40ul) / Day9 \~ Day100 / BID
Study NCT02967614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [A]+[B](2)
Description: One eye drop(about 40ul) / Day93 \~ Day100 / BID
Study NCT03811561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
Study NCT03811561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
Study NCT02398968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron fumerate
Description: iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
Study NCT00664937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: montelukast sodium
Description: single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
Study NCT00664937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: single oral dose, before exercise challenge, of Pbo; 7 week duration.
Study NCT04512768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Internet-delivered Cognitive Behaviour Therapy
Description: All participants receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. The course is comprised of 5 lessons, beginning with psychoeducation and an introduction to the cognitive behavioural model, and then introducing key skills for managing anxiety and depression, including thought challenging, de-arousal strategies, graded exposure, behavioural activation, and relapse prevention. The course also includes supplementary resources that briefly provide information on related common concerns, such as managing worry, communication, assertiveness, problem solving, and a brief resource on sleep that provides limited psychoeducation and sleep hygiene information. Participants receive weekly brief therapist support via secure message or telephone from qualified counselors (social workers, psychologists).
Study NCT04512768 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic Internet-delivered Cognitive Behaviour Therapy
Description: All participants receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. The course is comprised of 5 lessons, beginning with psychoeducation and an introduction to the cognitive behavioural model, and then introducing key skills for managing anxiety and depression, including thought challenging, de-arousal strategies, graded exposure, behavioural activation, and relapse prevention. The course also includes supplementary resources that briefly provide information on related common concerns, such as managing worry, communication, assertiveness, problem solving, and a brief resource on sleep that provides limited psychoeducation and sleep hygiene information. Participants receive weekly brief therapist support via secure message or telephone from qualified counselors (social workers, psychologists).
Study NCT04512768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Internet-Delivered Cognitive Behaviour Therapy for Insomnia
Description: A new sleep lesson will replace the existing resource, developed using a patient-oriented process, that provides information and skills to aid with insomnia. The sleep lesson includes psychoeducation on the nature of sleep problems and factors that affect sleep, such as circadian rhythm. Two key behavioural strategies are introduced: sleep restriction, which requires the patient to avoid napping and sleep on a strict schedule for several weeks until they begin to feel naturally sleepy at night; and stimulus control, which asks the participant to only spend time in bed when prepared to sleep and avoid other activities (e.g., work, TV) in bed. Patients will record how much they sleep each night and provide ratings of sleep quality and fatigue each week. Therapists will support patients in adjusting their sleep schedule. Patients are encouraged to apply skills they learn during the Wellbeing Course to sleep problems, for example, by applying thought challenging to beliefs about sleep.
Study NCT00546390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Pressure Cuff
Description: The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
Study NCT02200900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal pressure
Description: Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.
Study NCT02200900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous carbon dioxide
Description: Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.
Study NCT02200900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal gas concentrations
Description: Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
Study NCT03707951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)
Study NCT03707951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
Study NCT01497405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)
Description: TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
Study NCT01497405 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Test, Treat, Retain(TTR) only
Description: TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
Study NCT03032172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally once daily.
Study NCT04544410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily
Study NCT04544410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily
Study NCT02200900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume
Description: Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
Study NCT05002907 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: After signing the informed consent sheet, a standardized face-to-face questionnaire will be conducted by the doctor, nurse or coordinator to collect socio-demographic data, lifestyle data, sex life and other potential risk factors and knowledge about viral hepatitis.
Study NCT05002907 — intervention group
Intervention type: OTHER
Intervention: Biocollection
Description: After answering the questionnaire, the nurse or the doctor will take a sample of capillary blood from the fingertip on the side of the distal phalanx of a middle or ring finger. The puncture site will be prepared by warming and massage to optimize blood flow and disinfected with a disposable 70% alcohol wipe. After drying, the puncture will be performed using a single use safety lancet. A total of 7 capillary blood spotswill be collected and deposited on the filter paper (each spot is about 50µL of capillary blood), 5 for the study and 2 for the biological collection.
Study NCT05002907 — intervention group
Intervention type: OTHER
Intervention: Delivery of results
Description: After receiving the individual biological analysis results, in coded form (results only identified by the anonymity number), at the investigation center and lifting the anonymity by the coordinator of the study in each study center (in Cayenne or Paramaribo depending the country where the inclusion took place) with the help of the correspondance list, the participants' results will be delivered to the referral doctor of each health centre and the infectious disease specialist responsible for each area of inclusion. All positive participants will be contacted if they do not spontaneously come to retrieve their results (within approximately 1 month after result's availability), and invited to come to the health centre to retrieve their results individually and be oriented towards the heathcare circuit.
Study NCT05002907 — intervention group
Intervention type: OTHER
Intervention: Results and advices on transmission prevention methods
Description: The results will be revealed by the health centre's doctor/infectiologist, individually and confidentially, with an explanation of the results and advices on transmission prevention methods.Non-immunized patients against HBV will be offered a status determination (Anti-HBs Ab quantification on whole blood sample) and if necessary a catch-up vaccination according to the national immunization schedule.
Study NCT05002907 — intervention group
Intervention type: OTHER
Intervention: Confirmation of results on a blood test (In the event of a positive result)
Description: In case of a positive result, the doctor will explain the need to confirm these results on a blood test, prescribe the initial assessment and take an appointment with the infectious disease specialist. He will guide the patient towards accompaniment for the opening of medical coverage rights if necessary and support by an association if desired.
Study NCT05002907 — intervention group
Intervention type: OTHER
Intervention: Information for care
Description: A document with all contact information for a comprehensive and specialized care (professionals and associations for access to medical coverage and support, associations proposing support, general practitioners and specialists) will be given to positive participants. Patient monitoring and treatment will be carried out according to the national guidelines in each country.
Study NCT05002907 — intervention group
Intervention type: OTHER
Intervention: Monitoring and treatment
Description: Consequently, all positive participants will be able to be monitored and treated by a specialist of the disease. They will give post-test counselling and will conduct patient follow-up and treatment according to the usual standards of care of each country.
Study NCT00642538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC253 Inhalation Powder
Description: Inhalation Powder, prandial
Study NCT00764036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate
Description: add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
Study NCT02488343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Three types of intervention will be used: a) Interventions aimed to dealing with cognitions and habits will be based on cognitive-behavioral therapy (CBT) principles. b) Interventions aimed to dealing with affective factors that interfere with adherence will be based on dynamic therapy, crisis intervention and supportive elements. c) In the case of condition-related or therapy related barriers to adherence, psycho-educational multidisciplinary interventions of 1-2 appointments will be offered. Education about injection techniques and about reasonable expectations from therapy, and from MS itself, are a key strategy to successfully maintaining adherence.
Study NCT04610567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate-LDE phase 1
Description: 3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
Study NCT04610567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate-LDE phase 2
Description: 44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
Study NCT04610567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-LDE phase 2
Description: 44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
Study NCT02727777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK228
Description: Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.
Study NCT00642538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Technosphere Inhalation Powder
Description: Inhalation Powder, prandial
Study NCT00642538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous injection
Description: 10µg Exenatide, prandial
Study NCT03348215 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treadmill Training
Description: 6 week programme of treadmill training with addition of an immersive environment (virtual reality projection), body weight support, orthotics and functional electrical stimulation
Study NCT02727777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sugar Testing
Description: Participant given a glucometer to check pre-dose blood sugar levels at home every day.
Study NCT00647738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Single-dose 20 mg immediate-release oral tablets
Study NCT00647738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Single-dose 20 mg immediate-release oral tablet
Study NCT00839813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 10 weeks of a trauma-sensitive yoga class
Study NCT02776436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose of prophylactic dexamethasone will be reduced for all patients
Study NCT02776436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: standard prednisone 5 mg bid for patients with prostate cancer
Study NCT03728426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Patients will receive intravenous or oral letermovir at a dose of 480mg/day.~Patients weighing 40 or more kilograms will receive a second, loading, dose 12 hours after the first dose of letermovir treatment.~For patients receiving concomitant cyclosporine treatment, the letermovir dose will be 240mg/day.
Study NCT05581940 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Group A Caudal Epidural Anesthesia with bupivacaine 0.25% and group B with opioid intervenors
Description: (CEB) in group A using drugs bupivacaine 0.25% commonly used in children including neonates in group A In infraumbilical operations, it is used as a supplement to GA and to control postoperative pain It is a safe, easy, and effective type of central neuraxial block.\[ The patient will be intubated and the caudal block will be performed under GA after securing the airway. The patient's position will be turned onto the lateral decubitus then a landmark-based, blind technique will be used. In children, the success rate with the blind technique is above 96% but the occurrence of side effects is reported. Group B uses general anesthesia (GA) alone for intraoperative and perioperative pain control used the opioid intervious without caudal block .
Study NCT03363464 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT03363464 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: dipeptidyl peptidase-4 inhibitor
Study NCT03363464 — intervention group
Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Glucagon-like peptide-1 receptor agonist
Study NCT02231190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
Study NCT02231190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
Study NCT03842371 — intervention group
Intervention type: OTHER
Intervention: Metabolic level of BCAAs in monocytes and macrophages
Description: Metabolic level of BCAAs in monocytes and macrophages
Study NCT01926613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking Skills for Work Program
Description: The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and supported employment services.
Study NCT01926613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported Employment
Description: Supported Employment is an evidence based vocational rehabilitation program
Study NCT04074200 — intervention group
Intervention type: PROCEDURE
Intervention: Open Inguinal Hernia Repair
Description: With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
Study NCT04074200 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Inguinal Hernia Repair
Description: With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
Study NCT04266587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: blood sampling is done on healthy volunteers
Study NCT02698332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm for UTI
Description: The algorithm consists of one sheet of laminated paper with instruction in how to diagnose UTI
Study NCT04074200 — intervention group
Intervention type: DEVICE
Intervention: Robotic-Assisted Inguinal Hernia Repair
Description: With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
Study NCT04892784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press tack needle acupuncture
Description: Pyonex press tack needle sized 0.20x1.2mm
Study NCT00423384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00423384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: I.v.
Study NCT02318498 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CMR
Description: Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping